Outset Medical

Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

WHITMORE LAKE, Mich.--(BUSINESS WIRE)--Trace Medical, the national leader in advanced respiratory rentals and biomedical services, has announced a long-term distribution agreement with Outset Medical to rent the Tablo® Hemodialysis System to Home Medical Equipment (HME) providers. As part of this agreement, Trace Medical will leverage its national distribution network to offer HME providers exclusive access to rent Tablo and meet the growing demand of dialysis patients seeking treatment at home.

Trace Medical & Outset Medical sign long-term distribution agreement for Tablo® Hemodialysis System

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023 at 11:55am PT / 2:55pm ET. A live and archived webcast of the fireside chat will be available on the “Investors” section of the.

Outset Medical to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK , Aug. 17, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Outset Medical, Inc. (NASDAQ: OM) resulting from allegations that Outset Medical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Outset Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Outset Medical, Inc. Investors to Inquire About Securities Class Action Investigation - OM

LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ: OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK , Aug. 3, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Outset Medical, Inc. (NASDAQ: OM) resulting from allegations that Outset Medical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Outset Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

OM LOSS ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Outset Medical, Inc. Investors to Inquire About Securities Class Action Investigation - OM

LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Outset Medical, Inc. (NASDAQ:OM ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Jim Mazzola - Vice President, Investor Relations Leslie Trigg - Chair & Chief Executive Officer Nabeel Ahmed - Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Rick Wise - Stifel Shagun Singh - RBC Capital Markets Suraj Kalia - Oppenheimer & Company Josh Jennings - TD Cowen Drew Ranieri - Morgan Stanley Operator Good day, and thank you for standing-by. Welcome to Outset Medical Q2 2023 Earnings Conference Call.

Outset Medical, Inc. (OM) Q2 2023 Earnings Call Transcript

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.77 per share a year ago.

Outset Medical, Inc. (OM) Reports Q2 Loss, Tops Revenue Estimates

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Recorded net revenue of $36.0 million in the second quarter, a 44% increase compared to $25.1 million in the second quarter of 2022, and an 8% increase compared to $33.5 million in the fir.

Outset Medical Reports Second Quarter 2023 Financial Results

LOS ANGELES, CA / ACCESSWIRE / August 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK , July 27, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Outset Medical, Inc. (NASDAQ: OM) resulting from allegations that Outset Medical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Outset Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Outset Medical, Inc. Investors to Inquire About Securities Class Action Investigation - OM

NEW YORK , July 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM

LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Outset Medical, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Outset investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit yo.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Outset Medical, Inc. (OM) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) investors concerning the Company's possible violations of federal securities laws. On July 7, 2023, Outset Medical disclosed that it had received a Warning Letter from the United States Food and Drug Administration (“FDA”) which “assert[ed] that certain materials reviewed by the FDA and found on the Company's website promot.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Outset Medical, Inc. (OM) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On July 7, 2023, Outset Medical disclosed that it had received a Warning Letter from the United States Food and Drug Administration (“FDA”) which “assert[ed] that cer.

The Law Offices of Frank R. Cruz Continues Its Investigation of Outset Medical, Inc. (OM) on Behalf of Investors

Outset Medical Inc's share price has risen by over 11% over the past year, but the company lacks a positive bottom line, making it a risky investment. The company, which develops hemodialysis systems for dialysis, recently reported revenues of $33.5 million, a 9.5% increase YoY, and gross margins of 19.2%. Despite its cutting-edge technology and large total addressable market, the company's negative net margins and speculative nature make it a hold rather than a buy for the moment.

Outset Medical: Expansive TAM, Yet Profitability Remains Distant

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Outset Medical, Inc. (NASDAQ: OM) resulting from allegations that Outset Medical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Outset Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee.

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Outset Medical, Inc. Investors to Inquire About Securities Class Action Investigation – OM

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter of 2023 after the close of trading on Wednesday, August 2, 2023. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, w.

Outset Medical to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023

Outset said it received a Warning Letter from the FDA last week. The letter raised two new concerns regarding the company's dialysis products.

Why Shares of Outset Medical Are Down Monday

Markets were generally slightly higher by midmorning on Monday. FMC warned that its quarterly financial results wouldn't be as strong as anticipated.

Shareholders in These 2 Stocks Got Nasty Surprises Monday

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 8:00am PT / 11:00am ET. A live and archived webcast of the fireside chat will be available on the “Investors” section of the Out.

News for Outset Medical Stock (OM)